Advisors Asset Management
LYEL icon

Advisors Asset Management’s Lyell Immunopharma LYEL Stock Holding History

Advisors Asset Management’s Portfolio LYEL Stock Details LYEL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-567
Closed -$11.4K – 1456
2026
Q1 		$11.4K Hold
567
– – ﹤0.01% 1384
2025
Q4 		$17.5K Hold
567
– – ﹤0.01% 1362
2025
Q3 		$9.21K Sell
567
-8
-1% -$91 ﹤0.01% 1385
2025
Q2 		$5.08K Sell
575
-6
-1% -$55 ﹤0.01% 1408
2025
Q1 		$6.25K Buy
+581
New +$7.12K ﹤0.01% 1429

Other funds holding LYEL

AVM
Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return
GP
GSK plc London $602M AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
OPL
Orland Properties Ltd Road Town, Tortola, British Virgin Islands $202M AUM 2.79% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $732M AUM 275.56% 1-Year Est. Return
AC
Almitas Capital Santa Monica, California $417M AUM 22.81% 1-Year Est. Return
FCMV
Foresite Capital Management V Larkspur, California $362M AUM 386.37% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return

Advisors Asset Management's LYEL Position: Q2 2026 in Review

Advisors Asset Management sold out of Lyell Immunopharma (LYEL) in Q2 2026, closing a stake of 567 shares — an estimated $11.4K sold.

Advisors Asset Management first reported a position in LYEL in Q1 2025 and held it in 5 quarters. The position peaked at $17.5K in Q4 2025. 87 funds tracked by Wall St. Rank hold LYEL as of Q2 2026.

  • Advisors Asset Management reported no remaining Lyell Immunopharma position as of Q2 2026 after selling out during the quarter.
  • Advisors Asset Management sold 567 Lyell Immunopharma shares in Q2 2026, an estimated $11.4K.
  • Advisors Asset Management first reported a position in Lyell Immunopharma in Q1 2025 and held it in 5 quarters.
  • Advisors Asset Management's Lyell Immunopharma position peaked at $17.5K in Q4 2025.
  • 87 funds tracked by Wall St. Rank held Lyell Immunopharma as of Q2 2026.

Based on Advisors Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.